Identification of surgical smoke

Patent metadata

Field	Value
Publication number	US-9255907-B2
Application number	US-201314363049-A
Country	US
Kind code	B2
Filing date	Mar 14, 2013
Priority date	Mar 14, 2013
Publication date	Feb 9, 2016
Grant date	Feb 9, 2016

Abstract

A method includes assessing tumor margins and discriminating between tumor and non-tumor tissues by analyzing the compositional make-up of smoke produced during cautery resection of tissues.

First claim

What is claimed is:

1. A method for assessing the completeness of tumor resection in a subject, the method comprising:
introducing to the subject a marker that binds tumor tissue to a greater extent than non-tumor tissue;
cauterizing along the boundaries of a tumor to generate a cautery smoke; and
comparing a concentration of the marker in the cautery smoke to a predetermined concentration for the marker in a non-tumor tissue to assess the completeness of tumor resections;
wherein the tumor is completely resected before said cauterizing the tissue along the boundaries of the tumor.

2. The method of claim 1 , wherein the marker is introduced by intravenous injection, by intratumoral injection, by inhalation, or by oral administration.

3. The method of claim 1 , wherein the tumor is completely resected when the concentration of the marker in the cautery smoke corresponds to the concentration of the marker in normal tissue.

4. The method of claim 1 , wherein the tumor marker comprises a perfluorinated alkane.

5. The method of claim 4 , wherein the perfluorinated alkane comprises at least one of perfluoroethane, perfluoropropane, perfluoro-isopropane, perfluorobutane, perfluro-isobutane, perfluoro-tertiarybutane, perfluoropentane, perfluoro-isopentane, perfluorohexane, perfluorooctyl bromide, or perfluoro-neopentane.

6. The method of claim 1 , wherein the tumor marker is encapsulated in a plurality of microbubbles, wherein the microbubbles comprise a thermally degradable polymer.

7. The method of claim 6 , wherein the thermally degradable polymer comprises at least one of methylcyanoacrylate, methoxyethyl cyanoacrylate, polymethacrylic acid, or polyethylene glycol.

8. The method of claim 1 , wherein the tumor tissue comprises liver tissue.

9. The method of claim 1 , wherein the tumor marker is a tumor-specific antibody, a fluorescently labeled antibody, a radioactive antibody, or an antibody specific for hepatocellular carcinoma.

10. The method of claim 1 further comprising waiting for a sufficient period between introducing and contacting, to allow the tumor marker to bind to tumor tissue.

11. The method of claim 1 further comprising administering one or more agents that enhance the selective binding of the tumor marker to the tumor tissue, the agent comprising a tumor selective peptide, a cell penetrating peptide, or a chemical substance.

12. The method of claim 11 , wherein the tumor marker is a chemical substance.

13. The method of claim 12 , wherein the chemical substance is a microbubble of perfluorobutane.

14. The method of claim 12 , wherein the chemical substance is transported to the tumor tissue by active transport or passive transport.

15. The method of claim 12 , wherein the chemical substance is transported to the tumor tissue by active transport and accumulates within the vicinity of the tumor tissue.

Assignees

• Empire Technology Dev Llc

Inventors

• Heanue Joseph Anthony
• Funk Tobias
• Bechtel Kate Leeann
• Parashar Amish

Classifications

• A61B18/082 Primary

  Probes or electrodes therefor · CPC title

• H01J49/0031

  Step by step routines describing the use of the apparatus (H01J49/0081 takes precedence) · CPC title

• A61B18/14

  Probes or electrodes therefor · CPC title

• G01N21/6486

  Measuring fluorescence of biological material, e.g. DNA, RNA, cells (G01N21/6428 takes precedence) · CPC title

• A61B2018/00898

  Alarms or notifications created in response to an abnormal condition · CPC title